William Oh, MD, Deputy Director of The Tisch Cancer Institute, Chairman of Hematology and Medical Oncology, and Professor of Medicine and Urology, discusses the importance of androgen deprivation therapy for metastatic hormone-sensitive prostate cancer and choosing the most appropriate treatment strategies.
